H
Halle C. F. Moore
Researcher at Cleveland Clinic
Publications - 106
Citations - 3568
Halle C. F. Moore is an academic researcher from Cleveland Clinic. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 24, co-authored 85 publications receiving 2372 citations. Previous affiliations of Halle C. F. Moore include MetroHealth & Case Western Reserve University.
Papers
More filters
Journal ArticleDOI
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
Shanu Modi,William Jacot,Toshinari Yamashita,Joohyuk Sohn,Maria Vidal,Eriko Tokunaga,Junji Tsurutani,Naoto Ueno,Aleix Prat,Yee Soo Chae,Keun Seok Lee,Naoki Niikura,Yeon Hee Park,Bing Xue,Xiao-juan Wang,Miguel Gil-Gil,Wei Liu,Jean-Yves Pierga,Seock-Ah Im,Halle C. F. Moore,Hope S. Rugo,Rinat Yerushalmi,Flora Zagouri,Andrea Gombos,Sung-Bae Kim,Qiang Liu,Ting Luo,Cristina Saura,Peter Schmid,Tao Sun,Dhiraj Gambhire,Lotus Yung,Yibin Wang,Jasmeet Singh,Patrik Vitazka,Gerold Meinhardt,Nadia Harbeck,David Cameron +37 more
TL;DR: In this phase 3 trial involving patients with HER2-low metastatic breast cancer, trastuzumab deruxtecan resulted in significantly longer progression-free and overall survival than the physician's choice of chemotherapy.
Journal ArticleDOI
Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.
Halle C. F. Moore,Joseph M. Unger,Kelly-Anne Phillips,Frances M. Boyle,Frances M. Boyle,Erika Hitre,David L. Porter,Prudence A. Francis,Lori J. Goldstein,Henry L. Gomez,Carlos S. Vallejos,Ann H. Partridge,Shaker R. Dakhil,Agustin A. Garcia,Julie R. Gralow,Janine M. Lombard,John F. Forbes,Silvana Martino,William E. Barlow,Carol J. Fabian,Lori M. Minasian,Frank L. Meyskens,Richard D. Gelber,Gabriel N. Hortobagyi,Kathy S. Albain +24 more
TL;DR: Although missing data weaken interpretation of the findings, administration of goserelin with chemotherapy appeared to protect against ovarian failure, reducing the risk of early menopause and improving prospects for fertility.
Journal ArticleDOI
Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient–Level Data
Matteo Lambertini,Halle C. F. Moore,Robert C. F. Leonard,Sibylle Loibl,Pamela N. Munster,Marco Bruzzone,Luca Boni,Joseph M. Unger,Richard A. Anderson,Keyur Mehta,Susan Minton,Francesca Poggio,Kathy S. Albain,Douglas Adamson,Bernd Gerber,Amy Cripps,Gianfilippo Bertelli,Sabine Seiler,Marcello Ceppi,Ann H. Partridge,Lucia Del Mastro +20 more
TL;DR: Evidence is provided for the efficacy and safety of temporary ovarian suppression with GnRHa during chemotherapy as an available option to reduce the likelihood of chemotherapy-induced POI and potentially improve future fertility in premenopausal patients with early breast cancer.
Journal ArticleDOI
Goserelin for Ovarian Protection During Breast-Cancer Adjuvant Chemotherapy
Halle C. F. Moore,Joseph M. Unger,Kelly-Anne Phillips,Frances M. Boyle,Frances M. Boyle,Erika Hitre,David L. Porter,Prudence A. Francis,Lori J. Goldstein,Henry L. Gomez,Carlos S. Vallejos,Ann H. Partridge,Shaker R. Dakhil,Shaker R. Dakhil,Agustin A. Garcia,Julie R. Gralow,Janine M. Lombard,John F. Forbe,Silvana Martino,William E. Barlow,Carol J. Fabian,Lori M. Minasian,Frank L. Meyskens,Richard D. Gelber,Gabriel N. Hortobagyi,Kathy S. Albain +25 more
TL;DR: The survival benefit of adjuvant chemotherapy in young women with operable hormone receptor–negative breast cancer is well known, but concern over becoming infertile may influence the choice of treatment.
Journal ArticleDOI
Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.
Adam Brufsky,Linda D. Bosserman,Richard R. Caradonna,Barbara Haley,C. Michael Jones,Halle C. F. Moore,Lixian Jin,Ghulam Warsi,Solveig G. Ericson,Edith A. Perez +9 more
TL;DR: Up-front ZA more effectively prevents AI-associated bone loss in postmenopausal women with early breast cancer than delaying therapy until substantial bone loss or fracture occurs.